MedPage Today on MSN

Novel Complement-Targeting Agent Shows Benefit in Myasthenia Gravis

The trial tested two doses of claseprubart -- 300 mg and 600 mg -- and its primary endpoint was safety. Secondary outcomes ...
FierceBiotech

Silence takes back 2 complement programs from Mallinckrodt after 3.5-year collaboration

Silence Therapeutics is snatching back two siRNA drug targets developed through a $20 million collaboration with Mallinckrodt. The two companies agreed in 2019 to develop three siRNA drug targets that ...